MaxCyte(MXCT) - 2025 Q2 - Quarterly Results

Exhibit 99.1 MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance ROCKVILLE, MD, August 6, 2025 — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell- engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2025 financial results and updated its 2025 guidance. Second Quarter and Recent Highlights "Despite solid growth ...